Physician profile
Eric J Marsh
NPI 1508853185
$7,637.77
in general payments reported to CMS, 2019-2025
36 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $523 · 2021: $305 · 2022: $630 · 2023: $1,266 · 2024: $1,466 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,327 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,327.18 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,063.17 | 2019-2025 | Otezla, Otezla |
| Abbvie INC. | $1,059.68 | 2019-2025 | |
| Lilly USA, LLC | $665.51 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $661.77 | 2019-2025 | |
| Janssen Biotech, INC. | $628.28 | 2019-2024 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $613.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $493.50 | 2019-2025 | |
| Ucb, INC. | $417.96 | 2020-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $391.78 | 2019-2025 | Libtayo, Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.12 | 2019-2023 | Arazlo |
| Dermira, INC. | $147.21 | 2019 | |
| Celgene Corporation | $117.56 | 2019 | |
| Genentech USA, INC. | $116.54 | 2019-2023 | Xolair |
| Galderma Laboratories, L.P. | $114.23 | 2019-2025 | Aklief, Nemluvio |
| Incyte Corporation | $105.52 | 2021-2024 | Opzelura |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $95.98 | 2020-2024 | Xepi, Bf-Rhodoled, Ameluz |
| E.R. Squibb & Sons, L.L.C. | $93.59 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $90.74 | 2019-2024 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.87 | 2023-2025 | Spevigo, Cyltezo |
| Helsinn Therapeutics (U.S.), INC. | $67.10 | 2019 | |
| Organon LLC | $57.56 | 2023-2025 | Hadlima, Nexplanon |
| Biocon Biologics INC | $41.37 | 2023-2024 | Hulio |
| Mayne Pharma Commercial LLC | $39.17 | 2019-2025 | |
| Pfizer INC. | $38.82 | 2019 | |
| Dermavant Sciences, INC. | $37.72 | 2023-2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $36.29 | 2024 | Nuzyra |
| Prugen, INC. Pharmaceuticals | $28.51 | 2019 | |
| Merck Sharp & Dohme LLC | $24.95 | 2025 | Keytruda |
| Smith+Nephew, INC. | $22.44 | 2019 | |
| Fresenius Kabi USA, LLC | $22.12 | 2023 | Idacio |
| Promius Pharma LLC | $21.50 | 2019 | |
| Arcutis Biotherapeutics, INC. | $16.08 | 2023 | |
| Dusa Pharmaceuticals, INC. | $14.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2025 | Simlandi |
| Allergan, INC. | $14.84 | 2022 | |
| Vyne Pharmaceuticals INC. | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.